Clinical Trial

NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
NBM-BMX is an orally available new chemical entity to inhibit histone deacetylases 8 (HDAC8) activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. This study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors or combination with the standard of care treatment in subjects with newly diagnosed glioblastoma.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-08-22; most recent amendment 2026-04-24.
Trial Details
NCT Number NCT06012695
Lead Sponsor Novelwise Pharmaceutical Corporation
Conditions Malignant Neoplasm, Malignant Neoplasm of Brain
Enrollment 79 participants
Start Date 2023-08-11
Primary Completion 2028-05-30 (estimated)
Study Completion 2029-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-29